Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors or cancer of the COLON.
Cancer or tumors of the MAXILLA or upper jaw.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the anal gland.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer of the MOUTH.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the TONGUE.
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
Tumors or cancer of the STOMACH.
Tumors or cancer of the URINARY BLADDER.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Tumors or cancer of the VAGINA.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
Experimentally induced tumors of the LIVER.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A malignant epithelial tumor with a glandular organization.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Tumors or cancer of the PARANASAL SINUSES.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
Tumors or cancer of the human BREAST.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
Neoplasms of the bony orbit and contents except the eyeball.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.
Tumors or cancer of the BRONCHI.
Tumors or cancer of the PERITONEUM.
Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
Neoplasms of the bony part of the skull.
Tumors or cancer of the VULVA.
Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)
Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).
Tumors or cancer of the LIP.
A benign tumor of fibrous or fully developed connective tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the ADRENAL GLANDS.
Tumors or cancer of the pelvic region.
Tumors or cancer of the gallbladder.
The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.
Neoplasms composed of fibrous and epithelial tissue. The concept does not refer to neoplasms located in fibrous tissue or epithelium.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
RNA present in neoplastic tissue.
Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)
A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).
Tumors or cancer of the CECUM.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)
Tumors or cancer of the DIGESTIVE SYSTEM.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Liquid material found in epithelial-lined closed cavities or sacs.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A benign epithelial tumor of the LIVER.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.
A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Tumor or cancer of the MALE GENITALIA.
Intracranial tumors originating in the region of the brain inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brain stem, and related structures. Primary tumors of this region are more frequent in children, and may present with ATAXIA; CRANIAL NERVE DISEASES; vomiting; HEADACHE; HYDROCEPHALUS; or other signs of neurologic dysfunction. Relatively frequent histologic subtypes include TERATOMA; MEDULLOBLASTOMA; GLIOBLASTOMA; ASTROCYTOMA; EPENDYMOMA; CRANIOPHARYNGIOMA; and choroid plexus papilloma (PAPILLOMA, CHOROID PLEXUS).
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
Tumors or cancer of the RECTUM.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Tumors or cancer of the ESOPHAGUS.
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A usually benign tumor made up predominantly of myoepithelial cells.
Tumors or cancer of the PROSTATE.
Tumors of cancer of the EYELIDS.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. (1/40131)

The cyclin-dependent kinase inhibitor p21waf1/Cip1 is a downstream effector of the p53-dependent cell growth arrest. We report herein that p21 was cleaved by caspase-3/CPP32 at the site of DHVD112L during the DNA damage-induced apoptosis of cancer cells. The cleaved p21 fragment could no more arrest the cells in G1 phase nor suppress the cells undergoing apoptosis because it failed to bind to the proliferating cell nuclear antigen (PCNA) and lost its capability to localize in the nucleus. Thus, caspase-3-mediated cleavage and inactivation of p21 protein may convert cancer cells from growth arrest to undergoing apoptosis, leading to the acceleration of chemotherapy-induced apoptotic process in cancer cells.  (+info)

Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. (2/40131)

BACKGROUND: Depressed respiratory function and respiratory symptoms are associated with impaired survival. The present study was undertaken to assess the relation between respiratory symptoms and mortality from cardiovascular causes, cancer and all causes in a large population of middle-aged men. METHODS: Prospective population study of 6442 men aged 51-59 at baseline, free of clinical angina pectoris and prior myocardial infarction. RESULTS: During 16 years there were 1804 deaths (786 from cardiovascular disease, 608 from cancer, 103 from pulmonary disease and 307 from any other cause). Men with effort-related breathlessness had increased risk of dying from all of the examined diseases. After adjustment for age, smoking habit and other risk factors, the relative risk (RR) associated with breathlessness of dying from coronary disease was 1.43 (95% CI : 1.16-1.77), from stroke 1.77 (95% CI: 1.07-2.93), from any cardiovascular disease 1.48 (95% CI : 1.24-1.76), cancer 1.36 (95% CI : 1.11-1.67) and from any cause 1.62 (95% CI: 1.44-1.81). An independent effect of breathlessness on cardiovascular death, cancer death and mortality from all causes was found in life-time non-smokers, and also if men with chest pain not considered to be angina were excluded. An independent effect was also found if all deaths during the first half of the follow-up were excluded. Men with cough and phlegm, without breathlessness, also had an elevated risk of dying from cardiovascular disease and cancer, but after adjustment for smoking and other risk factors this was no longer significant. However, a slightly elevated independent risk of dying from any cause was found (RR = 1.18 [95% CI: 1.02-1.36]). CONCLUSION: A positive response to a simple question about effort related breathlessness predicted subsequent mortality from several causes during a follow-up period of 16 years, independently of smoking and other risk factors.  (+info)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. (3/40131)

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of 5-fluorouracil (5-FU) catabolism. We report lymphocytic DPD data concerning a group of 53 patients (23 men, 30 women, mean age 58, range 36-73), treated by 5-FU-based chemotherapy in different French institutions and who developed unanticipated 5-FU-related toxicity. Lymphocyte samples (standard collection procedure) were sent to us for DPD determination (biochemical method). Among the whole group of 53 patients, 19 had a significant DPD deficiency (DD; below 150 fmol min(-1) mg(-1) protein, i.e. less than 70% of the mean value observed from previous population study). There was a greater majority of women in the DD group (15 out of 19, 79%) compared with the remaining 34 patients (15 out of 34, 44%, P<0.014). Toxicity was often severe, leading to patient death in two cases (both women). The toxicity score (sum of WHO grading, theoretical range 0-20) was twice as high in patients with marked DD (below 100 pmol min(-1) mg(-1) protein, n = 11, mean score = 13.2) compared with patients with moderate DD (between 150 and 100 pmol min(-1) mg(-1) protein, n = 8, mean score = 6.8), P = 0.008. In the DD group, there was a high frequency of neurotoxic syndromes (7 out of 19, 37%). The two deceased patients both had severe neurotoxicity. The occurrence of cardiac toxicity was relatively rare (1 out of 19, 5%). These data suggest that women are particularly prone to DPD deficiency and allow a more precise definition of the DD toxicity profile.  (+info)

Cancer incidence in the south Asian population of England (1990-92). (4/40131)

Cancer incidence among English south Asians (residents in England with ethnic origins in India, Pakistan or Bangladesh) is described and compared with non-south Asian and Indian subcontinent rates. The setting for the study was areas covered by Thames, Trent, West Midlands and Yorkshire cancer registries. The study identified 356 555 cases of incident cancer (ICD9:140-208) registered between 1990 and 1992, including 3845 classified as English south Asian. The main outcome measures were age specific and directly standardized incidence rates for all cancer sites (ICD9:140-208). English south Asian incidence rates for all sites combined were significantly lower than non-south Asian rates but higher than Indian subcontinent rates. English south Asian rates were substantially higher than Indian subcontinent rates for a number of common sites including lung cancer in males, breast cancer in females and lymphoma in both sexes. English south Asian rates for childhood and early adult cancer (0-29 years) were similar or higher than non-south Asian rates. English south Asian rates were significantly higher than non-south Asian rates for Hodgkin's disease in males, cancer of the tongue, mouth, oesophagus, thyroid gland and myeloid leukaemia in females, and cancer of the hypopharynx, liver and gall bladder in both sexes. The results are consistent with a transition from the lower cancer risk of the country of ethnic origin to that of the country of residence. They suggest that detrimental changes in lifestyle and other exposures have occurred in the migrant south Asian population.  (+info)

Cancer mortality by educational level in the city of Barcelona. (5/40131)

The objective of this study was to examine the relationship between educational level and mortality from cancer in the city of Barcelona. The data were derived from a record linkage between the Barcelona Mortality Registry and the Municipal Census. The relative risks (RR) of death and 95% confidence intervals (CIs) according to level of education were derived from Poisson regression models. For all malignancies, men in the lowest educational level had a RR of death of 1.21 (95% CI 1.13-1.29) compared with men with a university degree, whereas for women a significant decreasing in risk was observed (RR 0.81; 95% CI 0.74-0.90). Among men, significant negative trends of increasing risk according to level of education were present for cancer of the mouth and pharynx (RR 1.70 for lowest vs. highest level of education), oesophagus (RR 2.14), stomach (RR 1.99), larynx (RR 2.56) and lung (RR 1.35). Among women, cervical cancer was negatively related to education (RR 2.62), whereas a positive trend was present for cancers of the colon (RR 0.76), pancreas (RR 0.59), lung (RR 0.55) and breast (RR 0.65). The present study confirms for the first time, at an individual level, the existence of socioeconomic differences in mortality for several cancer sites in Barcelona, Spain. There is a need to implement health programmes and public health policies to reduce these inequities.  (+info)

p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. (6/40131)

p27kip1 (p27) is a member of the universal cyclin-dependent kinase inhibitor (CDKI) family. p27 expression is regulated by cell contact inhibition and by specific growth factors, such as transforming growth factor (TGF)-beta. Since the cloning of the p27 gene in 1994, a host of other functions have been associated with this cell cycle protein. In addition to its role as a CDKI, p27 is a putative tumor suppressor gene, regulator of drug resistance in solid tumors, and promoter of apoptosis; acts as a safeguard against inflammatory injury; and has a role in cell differentiation. The level of p27 protein expression decreases during tumor development and progression in some epithelial, lymphoid, and endocrine tissues. This decrease occurs mainly at the post-translational level with protein degradation by the ubiquitin-proteasome pathway. A large number of studies have characterized p27 as an independent prognostic factor in various human cancers, including breast, colon, and prostate adenocarcinomas. Here we review the role of p27 in the regulation of the cell cycle and other cell functions and as a diagnostic and prognostic marker in human neoplasms. We also review studies indicating the increasingly important roles of p27, other CDKIs, and cyclins in endocrine cell hyperplasia and tumor development.  (+info)

Angiogenesis: a new theory for endometriosis. (7/40131)

Excessive endometrial angiogenesis is proposed as an important mechanism in the pathogenesis of endometriosis. Evidence is reviewed for the hypothesis that the endometrium of women with endometriosis has an increased capacity to proliferate, implant and grow in the peritoneal cavity. Data is summarized indicating that the endometrium of patients with endometriosis shows enhanced endothelial cell proliferation. Results are also reviewed indicating that the cell adhesion molecule integrin alphavbeta3 is expressed in more blood vessels in the endometrium of women with endometriosis when compared with normal women. Taken together, these results provide evidence for increased endometrial angiogenesis in women with endometriosis when compared with normal subjects. Endometriosis is one of the family of angiogenic diseases. Other angiogenic diseases include solid tumours, rheumatoid arthritis, psoriasis and diabetic retanopathy. Excessive endometrial angiogenesis suggests novel new medical treatments for endometriosis aimed at the inhibition of angiogenesis.  (+info)

Osteopenia in the patient with cancer. (8/40131)

Osteopenia is defined as a reduction in bone mass. It is commonly known to occur in elderly people or women who are postmenopausal due to hormonal imbalances. This condition, however, can result because of many other factors, such as poor nutrition, prolonged pharmacological intervention, disease, and decreased mobility. Because patients with cancer experience many of these factors, they are often predisposed to osteopenia. Currently, patients with cancer are living longer and leading more fulfilling lives after treatment. Therefore, it is imperative that therapists who are responsible for these patients understand the risk factors for osteopenia and their relevance to a patient with cancer.  (+info)

Glutamine and glutamate are known to play important roles in cancer biology. However, no detailed information is available in terms of their levels of involvement in various biological processes across different cancer types, whereas such knowledge could be critical for understanding the distinct characteristics of different cancer types. Our computational study aimed to examine the functional roles of glutamine and glutamate across different cancer types. We conducted a comparative analysis of gene expression data of cancer tissues versus normal control tissues of 11 cancer types to understand glutamine and glutamate metabolisms in cancer. Specifically, we developed a linear regression model to assess differential contributions by glutamine and/or glutamate to each of seven biological processes in cancer versus control tissues. While our computational predictions were consistent with some of the previous observations, multiple novel predictions were made: (1) glutamine is generally not involved in
Data & statistics on Incidence Rates for Major Cancer Sites by Gender: Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Gender and Province, Canada, 2002, Incidence Rates for Major Cancer Sites by Gender, Estimated Age-Standardized Incidence Rates for Major Cancer Sites by Sex and Province, Canada, 2006...
Cancer researchers warned Monday that the number of elderly cancer patients would likely double from 2000 to 2030, creating huge challenges to healthcare systems worldwide.
TY - JOUR. T1 - Glypican 3 expression in pediatric malignant solid tumors. AU - Kinoshita, Yoshiaki. AU - Tanaka, Sakura. AU - Souzaki, Ryota. AU - Miyoshi, Kina. AU - Kohashi, Kenichi. AU - Oda, Yoshinao. AU - Nakatsura, Tetsuya. AU - Taguchi, Tomoaki. PY - 2015/2. Y1 - 2015/2. N2 - Purpose Glypican 3 (GPC3) is one of the cell surface heparan sulfate proteoglycans that binds to the cell membrane, and it is known as an oncofetal protein in adult malignant tumors. Clinical trials using a GPC3 peptide vaccine have already been started in Japan as a new immunotherapy for hepatocellular carcinoma in adult patients. To investigate the possibility of GPC3 immunotherapy for pediatric malignant tumors, we assessed the expression of GPC3 in pediatric malignant tumors. Methods Immunohistochemically, the GPC3 expression was examined in 159 pediatric solid tumors, including 35 cases of neuroblastoma, 30 cases of Wilms tumor, 10 cases of hepatoblastoma, 25 cases of germ cell tumors, 56 cases of ...
To the best of our knowledge, this was the first study to estimate the frequency of renal insufficiency in elderly cancer patients in Brazil. The prevalence of abnormal renal function among our cohort was high. As suspected, the absolute creatinine level does underestimate renal function impairment …
The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH Clinical Center treatment protocol.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a clinical protocol at the NIH Clinical Center.. OR. The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a clinical protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.. OR. The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel ...
Undergoing treatment for pediatric cancer can be a daunting experience for patients and their families. But thanks to one Business School undergrad, some of UNCs youngest and bravest patients are getting by with a little help from their friends.. Participating in a service activity for Business Cares - UNC Kenan-Flaglers signature philanthropy initiative - was an eye-opening experience for Alex Pritts (BSBA 17). He listened intently as Elise Herman shared her son Coopers five-year battle with brain cancer - the inspiration behind Super Coopers Little Red Wagon Foundation.. As Cooper underwent treatment, Herman and her husband Justin (MBA 05) discovered the unique challenges faced by pediatric cancer patients and their families. They also came to realize that few organizations provide the resources and assistance these families need most - and they were determined to help.. In 2010, the Herman family launched Super Coopers Little Red Wagon Foundation. Its apartment-style accommodations - ...
This pharmacokinetic study of nivolumab showed that there is little ethnic difference in the handling of nivolumab.Nivolumab was well tolerated in Korean patients.Background.This phase I study of nivolumab, an anti‐programmed cell death‐1 (anti‐PD‐1) monoclonal antibody, investigated the pharmacokinetics and safety of nivolumab in Korean patients with advanced solid tumors. Findings were compared with results from Japan and the U.S.Materials and Methods.In this two‐part study, patients received a single dose of nivolumab (1, 3, and 10 mg/kg; ONO‐4538‐13) and were followed up for 3 weeks. Those who met the required criteria proceeded to the second part (ONO‐4538‐14), and received the same dose as in part one every 2 weeks.Results.Six patients per dose level were enrolled (n = 18). The mean elimination half‐life of nivolumab among the groups ranged from 15.0 to 19.1 days. The maximum serum concentration and area under serum concentration-time curve increased almost ...
One of the things we do is we are part of the WHO specialised agency for cancer and for the last fifty years weve been developing statistics on the global burden of cancer. One of the key pieces that we work with WHO on is to develop the statistics and understand the future cancer burden as well. So we know there is going to be something in the order of thirty million new cancer cases by 2035, currently its about 14.1 million new cases. So the scale of cancer is increasing greatly, partially because of demographic effects, the impact of population aging and growth, but also increasing risk and the changing profile of cancers as well.. Thats important that we know that but we really need also local data and the best way to get better global data as well as local data is to support cancer surveillance, both in terms of incidence and mortality. We are buoyed by the high level impetus that we see for NCDs and cancers and governments now trying to tackle the increasing burden from NCDs and cancer. ...
Folakemi Odedina, Ph.D., a professor of pharmacy and the director of the UF Shands Cancer Centers Cancer Health Disparities Program, served on the planning committee for National Cancer Institute Global Cancer Research Day, which was held in Washington, DC in March in conjuction with the Consortium of Universities for Global Health Annual Meeting.. The meeting aimed to engage a diverse range of participants including both cancer researchers and global health professionals who may not necessarily have specific cancer expertise, but have an interest in exploring the intersection between global health and cancer. The Global Cancer Research Day meeting utilized a highly interactive format to engage the cancer research and global health communities in a rich dialogue about cross-cutting issues. Topics explored included capacity building, cancers related to infectious diseases (including HIV-related malignancies), lessons learned in global health and tapping into the global health communitys ...
Despite deep cuts in federal research spending due to sequestration, Associate Professor Muhammad Zaman (BME, MSE) has secured a five-year grant of more than $3 million from the National Institutes of Health to develop mathematical and computational models of how breast cancer cells move and communicate as they migrate from tumors, invade nearby tissue and proliferate.. By mapping this process from the molecular to the cellular level through detailed, comprehensive multiscale models based on strong experimental and computational data, Zaman and his collaborators-MIT Professors Frank Gertler, Roger Kamm and Douglas Lauffenberger, and a computational modeling team in Singapore-aim to uncover new pathways to control tumor development and metastasis in the breast, lung, and other organs.. Complex biochemical and biomechanical interactions govern how cancer cells spread from tumors and metastasize in nearby tissue. Much is known about the mechanics of how cancer cells migrate, but how biochemical ...
A new computational study shows how cancer cells take advantage of the system by which cells communicate with their neighbors as they pass messages to be like me or be not like me.. Cancer uses a little-understood element of cell signaling to hijack the communication process and spread, according to Rice University researchers.. Led by Rice biophysicists Eshel Ben-Jacob and José Onuchic, the researchers decode how cancer uses a cell-cell interaction mechanism known as notch signaling to promote metastasis. This mechanism plays a crucial role in embryonic development and wound healing and is activated when a delta or jagged ligand of one cell interacts with the notch receptor on an adjacent one.. Their open-access study appears this month in the Proceedings of the National Academy of Sciences. It follows a 2014 study in which the researchers mapped the flow of information through genetic circuits involved in cancer metastasis.. At the heart of our new understanding is that the primary ...
Allott, Emma H. et al Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. Cancer Prevention Research 10.6 (2017): 319-326. Web. 28 Sept2020. ...
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.. Experimental Design: In this phase I, open-label, dose-escalation study, patients received 35 to 160 mg of dasatinib twice daily in 28-day cycles either every 12 hours for 5 consecutive days followed by 2 nontreatment days every week (5D2) or as continuous, twice-daily (CDD) dosing.. Results: Sixty-seven patients were treated (5D2, n = 33; CDD, n = 34). The maximum tolerated doses were 120 mg twice daily 5D2 and 70 mg twice daily CDD. DLTs with 160 mg 5D2 were recurrent grade 2 rash, grade 3 lethargy, and one patient with both grade 3 prolonged bleeding time and grade 3 hypocalcemia; DLTs with 120 mg twice daily CDD were grade 3 nausea, grade 3 fatigue, and one patient with both grade 3 rash and grade 2 proteinuria. The most frequent treatment-related toxicities ...
Cancer therapies are designed to kill tumour cells, but produce tumour cell debris in the process.. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Womens Hospital and colleagues show that leftover debris can stimulate inflammation and tumour growth, but that molecules called resolvins can block that unwanted inflammatory response.. The findings point towards a new way to enhance the effectiveness of current cancer therapies and potentially prevent tumour recurrence.. When conventional cancer treatments, such as radiation or chemotherapy drugs, break apart tumours, they can also spread and stimulate the production of proinflammatory cytokines.. These signalling molecules, known to promote tumour growth, were at the centre of the investigation.. Dead and dying tumour cells are an under-appreciated component of the tumour microenvironment that may promote tumour progression, said Professor Charles Serhan, PhD, DSc, Department of Anesthesiology, ...
I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by investigating whether there were larger declines in the age-standardized mortality rate of cancer sites (breast, lung, colon, etc.) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate. The estimates indicate that new drugs launched during 1991-2001 reduced the age-standardized cancer mortality rate by 16%, i.e., at an average annual rate of about 1.6%. I estimate that 105,661 life-years before age 70 were gained in 2013 due to cancer drugs launched during 1991-2001, and that the cost per life-year gained was in the neighborhood of $2146. By the standards of the World Health Organization, new cancer drugs have been very cost-effective in Mexico. The contribution of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger. Only half as many new cancer drugs were
Figure_4_Graph_survival_black_22MAR18_Dead - Supplemental material for Presentation and Outcomes of Childhood Cancer Patients at Uganda Cancer Institute
Know the cost of Oncology Treatment in Kano. HEALGURU INDIA is associated with best Oncology Treatment Hospital in Kano and top surgeons in Kano. Book your appointment now
Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journals aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
Current Cancer Therapy Reviews publishes frontier reviews, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journals aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
Weve shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different that those in younger hosts, Dr. Curiel said. Weve shown that if you test all your immune therapy just in young mice and young people, youll never learn how it works in older patients - the ones most at risk for cancer. You might conclude that drugs dont work in aged hosts, when they do. But they have to be combined with some help.. After discovering this in melanoma, the researchers then looked at whether the same action held true in colon cancer, a major cancer killer in the elderly.. The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma, Dr. Curiel said. But the result was the same - we identified a drug combination that was highly effective in the aged mice.. That means that not only must this strategy be ...
Many of the worlds top cancer researchers presented the latest in cancer research when the Centre for Cancer Biomarkers invited to a two-day symposium at Solstrand.
... American Association for Cancer Research Aims to Raise Awareness a...PHILADELPHIA Sept. 24 /- ...News facts: ...-- Most Americans with cancer would be receptive to participating in...,Video:,The,Looming,Crisis,in,Cancer,Drug,Development:,97%,of,Adult,Cancer,Patients,Do,Not,Take,Advantage,of,Clinical,Trial,Programs,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Patient accrual. A phase I, single center, open-label design was used to assess the safety, PK characteristics, and efficacy of 2ME2. This study was conducted at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center after institutional review board approval. Patients ages ,18 y, with biopsy-proven disease, a life expectancy of ,3 mo, Karnofsky performance status of ,80%, and unresectable or metastatic solid malignancy were eligible. Patients were required to have either progressed on a previous therapy or to lack effective treatment options. Inclusion criteria included at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (15) or, in the case of patients with prostate cancer, an increasing serum level of prostate-specific antigen.. Exclusion criteria excluded hematopoietic (Hgb, ,10 g/dL; platelets, ,75,000/mm3), hepatic (aspartate aminotransferase or ALT of ,2.5 times the upper limit of normal) or renal (Cr of ,1.5 times upper limit of ...
This said, however, it is clear that work remains to be done in improving late effects. This may mean modifying current cancer treatments to reduce their neurotoxicity, or introducing new therapies and interventions for survivors. For those interested in developing new intervention strategies, the CCSS data is likely to prove an excellent starting point.. Findings from this study indicate that current therapies, with the continued goal of 100% cure, may still result in poor perceived health outcomes, and more work is needed to address these toxicities in treatment, says Ness. For those who develop adverse outcomes, rehabilitation strategies that work in other populations with pain and mobility limitations may be effective and need to be tested.. Already, several randomised intervention studies have been completed off the back of CCSS-based research. Having recruited a cohort of high-risk childhood cancer survivors, these studies looked into the benefits of breast cancer screening, ...
New research finds that gut bacteria affect cancer risk; in particular, an unhealthy gut flora balance may contribute to colorectal cancer.
Kulimova, Emma et al Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Molecular Cancer Therapeutics 5.12 (2006): 3105-3112. Web. 04 July. 2020. ...
Thank you for sharing this Molecular Cancer Therapeutics article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
The purpose of this study is to develop and pilot test a behavioral intervention for elderly adults in treatment for colon cancer, to enhance their skills for managing the challenges of completing chemotherapy regimens. The investigators will assess feasibility and acceptability of the intervention, and explore preliminary efficacy of the intervention for reducing psychological distress and improving rates of optimal chemotherapy adherence ...
Researchers have worked out how a new class of anticancer drugs can kill cancer cells. The findings also revealed more about how cancer cells resist treatment.
The researchers note that there will be about 89,500 new cancer cases and 9,270 cancer deaths in AYAs in 2020. During the most recent decade (2007 to 2016), overall cancer incidence increased in all AYA age groups, mainly driven by thyroid cancer. In most age groups, incidence also increased for several cancers linked to obesity, including kidney, uterine corpus, and colorectum. In those aged 15 to 29 years, rates declined dramatically for melanoma (4 to 6 percent annually). During 2008 through 2017, overall cancer mortality decreased by 1 percent annually across age and sex groups, apart from women aged 30 to 39 years who had stable rates. Across age groups, five-year relative survival in AYAs was similar for all cancers combined (range, 83 to 86 percent) but varied widely for some cancers.. Source: Read Full Article ...
The relationship between diet and exercise and its positive effects on treatment outcomes in obese cancer patients has sparked interest for quite some time, but for paediatric patients, the research has been limited.. While healthy eating is encouraged during and after treatment, special diet interventions as part of treatment for paediatric patients are uncommon.. Additionally, when it comes to physical activity, clinicians are cautious about administering an exercise regimen in a cancer care setting.. The purpose of the review was to delineate between obesity reduction as a goal for energy balance interventions versus simply changing diet or adding exercise, said Joya Chandra, Ph.D., associate professor of Paediatric Research and lead author on the study.. For example, our review confirmed modifying diet or adding moderate exercise can improve chemotherapy efficacy independent of weight loss.. Obesity, an epidemic and risk factor for several cancers, is on the rise in paediatric cancer ...
Background: Both dietary and serum levels of inorganic phosphate (Pi) have been linked to development of cancer in experimental studies. This is the first population-based study investigating the relation between serum Pi and risk of cancer in humans. Methods: From the Swedish Apolipoprotein Mortality Risk (AMORIS) study, we selected all participants (,20 years old) with baseline measurements of serum Pi, calcium, alkaline phosphatase, glucose, and creatinine (n = 397,292). Multivariable Cox proportional hazards regression analyses were used to assess serum Pi in relation to overall cancer risk. Similar analyses were performed for specific cancer sites. Results: We found a higher overall cancer risk with increasing Pi levels in men (HR: 1.02 (95% CI: 1.00-1.04) for every SD increase in Pi), and a negative association in women (HR: 0.97 (95% CI: 0.96-0.99) for every SD increase in Pi). Further analyses for specific cancer sites showed a positive link between Pi quartiles and the risk of cancer of ...
Jolly, Mohit Kumar et al E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms. Molecular Cancer Research (2019): molcanres.0763.2018. Web. 22 Jan. 2020. ...
Thank you for sharing this Molecular Cancer Research article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
TY - JOUR. T1 - Follow-Up Care Provider Preferences of Adolescent and Young Adult Cancer Survivors. AU - Ramsay, Joemy M.. AU - Mann, Karely. AU - Kaul, Sapna. AU - Zamora, Eduardo R.. AU - Smits-Seemann, Rochelle R.. AU - Kirchhoff, Anne C.. PY - 2018/4/1. Y1 - 2018/4/1. N2 - Purpose: To explore the experiences and perspectives of adolescent and young adult (AYA) cancer survivors regarding patient-provider relationships and their preferences surrounding type of healthcare provider for follow-up care. Methods: We recruited AYA cancer survivors who were diagnosed between the ages of 15 and 39 using the Utah Cancer Registry. Twenty-eight survivors participated in six focus groups held between March and May of 2015 in Salt Lake City and St. George, Utah. This analysis focuses on how survivors preferences about type of healthcare provider may influence their transition into, and utilization of, follow-up care. Results: On average, survivors were 6.3 (standard deviation = 1.7) years from their ...
An intensive, week-long introduction to translational cancer research - including cancer medicine, the clinical cancer research environment and collaborative team science - for basic scientists who are predoctoral students and postdoctoral fellows, early-career scientists and senior scientists in transition to translational research. This workshop is hosted in close collaboration with the Dana-Farber Cancer Institute/Harvard Cancer Center, comprised of Beth Israel Deaconess Medical Center, Brigham and Womens Hospital, Childrens Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health and Massachusetts General Hospital.. The Translational Cancer Research for Basic Scientists Workshop will provide basic research scientists with a better understanding of translational research, teach them how to adapt their research for maximum clinical impact and help them transition into a new career in translational cancer medicine. This innovative workshop ...
TY - JOUR. T1 - Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients. T2 - A systematic review and network meta-analysis. AU - Wilairat, Preyanate. AU - Kengkla, Kirati. AU - Kaewpanan, Thanatchai. AU - Kaewthong, Jirapat. AU - Ruankon, Sorave. AU - Subthaweesin, Chulalak. AU - Stenehjem, David D.. AU - Saokaew, Surasak. PY - 2020/3/1. Y1 - 2020/3/1. N2 - Objective: To examine the comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis (OM) in adult cancer patients. Methods: We searched PubMed, Embase and the Cochrane Central systematically for the randomised control trials (RCTs) of interventions for preventing OM. Network meta-analysis (NMA) was performed to estimate risk ratios (RR) and 95% confidence intervals (CI) from both direct and indirect evidence. The primary outcome was any grade of OM. Secondary outcomes were mild-moderate OM, severe OM and adverse events, such as ...
Translational Cancer Research publishes the results of novel research investigations including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers.
PURPOSE The adolescent and young adult (AYA) population is a growing group of survivors, exceeding more than 600,000, at high risk for late effects of cancer-directed therapy. While many guidelines exist for cancer survivorship care, choosing which to use for an AYA cancer survivor is challenging, yet vital, to ensure comprehensive follow-up care. METHODS Survivorship care plans (SCPs), including treatment summaries (TS) and follow-up care plans, were created for three clinical vignettes (acute lymphoblastic leukemia, osteosarcoma, and Hodgkin lymphoma). Four sets of guidelines were used, including the Childrens Oncology Group Long-Term Follow-Up Guidelines (COG LTFU), National Comprehensive Cancer Network (NCCN) Guidelines for Age- Related Recommendations: AYA Oncology (NCCN-AYA), NCCN Guidelines for Treatment of Cancer by Site (NCCN-Site), and NCCN Guidelines for Supportive Care: Survivorship (NCCN-Survivorship) and NCCN supplemental cancer screening guidelines. The follow-up care plans were
Young female cancer patients are unhappy about the way fertility preservation options are discussed with them by doctors before starting cancer treatment, according to a new study by researchers from the University of Sheffield and The Childrens Hospital, Sheffield.. The pioneering study discovered that only 40 per cent of young female cancer patients were happy with the way their doctors discussed the options they had to preserve fertility, before undergoing chemotherapy or radiotherapy which can have a harmful effect on a patients fertility.. Researchers conducted the ground breaking study by asking 290 young cancer patients attending support group conferences organised by the Teenager Cancer Trust in 2004 and 2011.. Their views were collected anonymously using Who wants to be a millionaire? style handsets to answer questions projected onto a big screen. All questions were answered by both male and female cancer patients aged between 13 and 22 years old who had been treated for a variety of ...
TY - JOUR. T1 - Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers. AU - Ge, Zhiyun. AU - Heitjan, Daniel F.. AU - Gerber, David E.. AU - Xuan, Lei. AU - Pruitt, Sandi L.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Surprisingly, survival from a diagnosis of lung cancer has been found to be longer for those who experienced a previous cancer than for those with no previous cancer. A possible explanation is lead-time bias, which, by advancing the time of diagnosis, apparently extends survival among those with a previous cancer even when they enjoy no real clinical advantage. We propose a discrete parametric model to jointly describe survival in a no-previous-cancer group (where, by definition, lead-time bias cannot exist) and in a previous-cancer group (where lead-time bias is possible). We model the lead time with a negative binomial distribution and the post-lead-time survival with a linear spline on the logit hazard scale, which allows for survival to differ between ...
According to the Global Cancer Immunotherapy Market report, the Cancer Immunotherapy Market accounted a value of $62.57 billion in 2016 and is projected to reach a value $160.24 billion at the end of 2023. The Global Cancer Immunotherapy Market report covers the Cancer Immunotherapy Market in a comprehensive manner, across all parameters such as types, applications, users, top players, and regions. The report further covers the drivers, restraints and trends in the Cancer Immunotherapy Market for the customer to understand the intricacies of the Cancer Immunotherapy Market which will help them create an efficient plan of action to grow at the fastest rate across the globe.. Browse The Report: http://orbisresearch.com/reports/index/cancer-immunotherapy-global-market-outlook-2017-2023. The Global Cancer Immunotherapy Market is expected to keep rising at a CAGR of 14.3% for the forecast period of 2017 - 2023. The Global Cancer Immunotherapy Market report provides the customer an accurate analysis ...
TY - JOUR. T1 - Phase i dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. AU - Lockhart, A. Craig. AU - Sundaram, Shankar. AU - Sarantopoulos, John. AU - Mita, Monica M.. AU - Wang-Gillam, Andrea. AU - Moseley, Jennifer L.. AU - Barber, Stephanie L.. AU - Lane, Alex R.. AU - Wack, Claudine. AU - Kassalow, Laurent. AU - Dedieu, Jean François. AU - Mita, Alain C.. PY - 2014/12/1. Y1 - 2014/12/1. N2 - Introduction Cabazitaxel is a second-generation taxane with in vivo activity against taxane-sensitive and -resistant tumor cell lines and tumor xenografts. Cabazitaxel/cisplatin have therapeutic synergism in tumor-bearing mice, providing a rationale for assessing this combination in patients with solid tumors. Methods The primary objectives of this study were to determine dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of a cabazitaxel/cisplatin combined regimen (Part 1) and to assess antitumor activity at the ...
The Translational Cancer Research for Basic Scientists Workshop will provide basic research scientists with a better understanding of translational research, teach them how to adapt their research for maximum clinical impact, and help them transition into a new career in translational cancer medicine. This innovative workshop addresses many aspects of translational research including leading multidisciplinary teams, working collaboratively and effectively with industry partners, recognizing the unique needs and environment of the clinic and clinical laboratories, dealing with the regulatory and compliance issues in translational science, and understanding the perspective of the patient in order to place research questions into a broader context. During the course of the week, attendees will gain perspective and background knowledge of the disease from translational scientists in academia and industry, clinicians, and patients, while learning about the latest methods and approaches in ...
Table of Content:. 1. INTRODUCTION. 1.1. OVERVIEW OF THE GLOBAL CANCER DIAGNOSTICS MARKET. 1.2. CURRENCY AND PRICING. 1.3. LIMITATION. 1.4. MARKETS COVERED. 2. MARKET SEGMENTATION. 2.1. KEY TAKEAWAYS. 2.2. ARRIVING AT THE GLOBAL CANCER DIAGNOSTICS MARKET SIZE. 2.2.1. MARKET CRACKDOWN APPROACH. 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS. 2.2.3. DATA TRIANGULATION. 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES. 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES. 2.2.6. PORTERS FIVE FORCES MATRIX. 2.2.7. PEST ANALYSIS. 2.2.8. EPIDEMIOLOGY FORECASTING MODELS. 2.3. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH SNAPSHOT. 2.4. ASSUMPTIONS. 3. MARKET OVERVIEW. 3.1. DRIVERS. 3.2. RESTRAINTS. 3.3. OPPORTUNITIES. 3.4. CHALLENGES. 4. EXECUTIVE SUMMARY. 5. PREMIUM INSIGHTS. 6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY. 6.1. OVERVIEW 6.2. PLATFORM BASED, BY PRODUCT TYPE. 6.2.1. POLYMERASE CHAIN REACTION (PCR). 6.2.2. IN SITU HYBRIDIZATION (ISH). 6.2.3. IMMUNOHISTOCHEMISTRY (IHC). 6.2.4. NEXT GENERATION ...
Table of Content:. 1. INTRODUCTION. 1.1. OVERVIEW OF THE GLOBAL CANCER DIAGNOSTICS MARKET. 1.2. CURRENCY AND PRICING. 1.3. LIMITATION. 1.4. MARKETS COVERED. 2. MARKET SEGMENTATION. 2.1. KEY TAKEAWAYS. 2.2. ARRIVING AT THE GLOBAL CANCER DIAGNOSTICS MARKET SIZE. 2.2.1. MARKET CRACKDOWN APPROACH. 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS. 2.2.3. DATA TRIANGULATION. 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES. 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES. 2.2.6. PORTERS FIVE FORCES MATRIX. 2.2.7. PEST ANALYSIS. 2.2.8. EPIDEMIOLOGY FORECASTING MODELS. 2.3. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH SNAPSHOT. 2.4. ASSUMPTIONS. 3. MARKET OVERVIEW. 3.1. DRIVERS. 3.2. RESTRAINTS. 3.3. OPPORTUNITIES. 3.4. CHALLENGES. 4. EXECUTIVE SUMMARY. 5. PREMIUM INSIGHTS. 6. GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY. 6.1. OVERVIEW 6.2. PLATFORM BASED, BY PRODUCT TYPE. 6.2.1. POLYMERASE CHAIN REACTION (PCR). 6.2.2. IN SITU HYBRIDIZATION (ISH). 6.2.3. IMMUNOHISTOCHEMISTRY (IHC). 6.2.4. NEXT GENERATION ...
Global Cancer Diagnostics Market to Reach $223. 3 Billion by 2027. Amid the COVID-19 crisis, the global market for Cancer Diagnostics estimated at US$150. 6 Billion in the year 2020, is projected to reach a revised size of US$223.New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report Global Cancer Diagnostics Industry - https://www.reportlinker.com/p05956209/?utm_source=GNW 3 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Laboratory Tests, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$50.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Genetic Tests segment is readjusted to a revised 6.4% CAGR for the next 7-year period. The U.S. Market is Estimated at $40.8 Billion, While China is Forecast to Grow at 8.8% CAGR The Cancer Diagnostics market in the U.S. is estimated at US
Background Partnership for Health-2 (PFH-2) is a web-based version of Partnership for Health, an evidence-based smoking cessation intervention for childhood cancer survivors. This paper describes the...
Survivors of the 10 most common cancers diagnosed in adolescents and young adults (AYAs) are at considerably higher risk for diseases.
The older age is characterized by the increase of frailty, physical comorbidities, functional limitations, cognitive deficits, and inability to perform activities of daily living [7-9]. In elderly cancer patients, there is a significant correlation between somatic diseases, functional limitations and psychological distress [9-11]. Anxiety and depression are considered the most common forms of psychological distress in elderly cancer patients with the highest prevalence in patients older than 80 years [7, 10, 11]. Furthermore, desease- and treatment-related symptoms and the awareness of living with an incurable malignancy can profoundly impact health-related quality of life [12].. In contrast to the amount of research available for patients with solid tumors, there is still a paucity of studies regarding health-related quality of life (HRQOL) in patients with hematologic malignancies [13-16]. For elderly hematologic cancer patients, the number of studies is even sparser. Although about every ...
Cancer-related fatigue is a subjective symptom of fatigue that is experienced by nearly all cancer patients. Among patients receiving cancer treatment other than surgery, it is essentially universal. Fatigue is a normal and expected side effect of most forms of chemotherapy, radiation therapy, and biotherapy. On average, cancer-related fatigue is more severe, more distressing, and less likely to be relieved by rest than fatigue experienced by healthy people. It can range from mild to severe, and may be either temporary or a long-term effect. Fatigue may be a symptom of the cancer, or it may be the result of treatments for the cancer. The National Comprehensive Cancer Network defines cancer-related fatigue as a distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. Cancer-related fatigue is a chronic fatigue (persistent ...
Children born to survivors of childhood cancer do not appear to have an increased risk of birth defects. These results were published in the Journal of Clinical Oncology.. Cancer treatment can have a range of reproductive effects. Treatment may result in a loss or reduction of fertility in men and women, and treatments that damage the uterus-such as radiation to the pelvis-may increase a womans risk of miscarriage or pre-term delivery. Studies of birth defects among children conceived after a parents cancer treatment have generally been reassuring, but not all of the studies considered the type and dose of treatment received by the parent.. To explore further the risk of birth defects among children born to cancer survivors, researchers evaluated information from the Childhood Cancer Survivor Study (CCSS). The childhood cancer survivors had been diagnosed with cancer before the age of 21. Information was available about almost 4,700 children born to these survivors. The children had been born ...
Lee, Laura R. et al Progesterone Enhances Calcitriol Antitumor Activity by Upregulating Vitamin D Receptor Expression and Promoting Apoptosis in Endometrial Cancer Cells. Cancer Prevention Research (2013): . Web. 22 Feb. 2020. ...
Mariah Carey blows through THREE OUTFITS during her Beverly Hills shopping spree. Bet hes Brad its all over! Cotterchio M, Kreiger N, Sloan M, Steingart A. Another study by researchers at the Dana-Farber Cancer Institute suggested that aspirin use prevents the development of cancers that have the normal version of a gene does ibuprofen increase cancer risk BRAFwhich does ibuprofen increase cancer risk been implicated as a key driver of several cancers, but not cancers that have a mutated form of the gene. Gigi Hadid cuts a casual figure in leather pants and an oversized sweater as she promotes her Tommy Hilfiger line ibuproofen London Fashion Week. Newsmax, Moneynews, Newsmax Health, and Independent.. ...
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.theTCR.org) is an Open Access, peer-reviewed journal, published by Pioneer Bioscience Publishing Company (PBPC), publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.theTCR.org) is an Open Access, peer-reviewed journal, published by Pioneer Bioscience Publishing Company (PBPC), publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.
TY - JOUR. T1 - Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. AU - Wang, Zhaoming. AU - Zhu, Bin. AU - Zhang, Mingfeng. AU - Parikh, Hemang. AU - Jia, Jinping. AU - Chung, Charles C.. AU - Sampson, Joshua N.. AU - Hoskins, Jason W.. AU - Hutchinson, Amy. AU - Burdette, Laurie. AU - Ibrahim, Abdisamad. AU - Hautman, Christopher. AU - Raj, Preethi S.. AU - Abnet, Christian C.. AU - Adjei, Andrew A.. AU - Ahlbom, Anders. AU - Albanes, Demetrius. AU - Allen, Naomi E.. AU - Ambrosone, Christine B.. AU - Aldrich, Melinda. AU - Amiano, Pilar. AU - Amos, Christopher. AU - Andersson, Ulrika. AU - Gerald Andriole, G. A.. AU - Andrulis, Irene L.. AU - Arici, Cecilia. AU - Arslan, Alan A.. AU - Austin, Melissa A.. AU - Baris, Dalsu. AU - Barkauskas, Donald A.. AU - Bassig, Bryan A.. AU - Freeman, Laura E.Beane. AU - Berg, Christine D.. AU - Berndt, Sonja I.. AU - Bertazzi, Pier ...
Centre for Translational Cancer Research news archive, read more news stories about cancer research by our researchers and colleagues at the University of Otago.
a) localized resectable- the tumor is located in one place (T1-T2),. b) localized unresectable - the tumor is present in one place however cannot be removed,. c) advanced - the tumor has spread to other organs,. d) recurrent - the cancer is back after treatment.. Unfortunately, liver cancer survival rates are low as the tumor can be undetected for a long time till any signs appear. More than a half of people affected are men; the common age of liver cancer is 60.. The liver cancer survival rates worldwide show that 7% of patients live up to 5 year after diagnosis. If the cancer is removed surgically, 75% of liver cancer patients can live one more year, 30% reach the survival mark of 5 years and 50% - 3 years.. In terms of primary cancer the liver cancer survival rates are quite high provided that a liver transplant can be performed. Liver cancer survival rates reach 5 years in 75% of cases. For metastatic cases liver transplants have a survival rate coming to zero because in some time cancer ...
LONDON - At present, the cancer diagnostics market is on the verge of explosion. Numerous remarkable technological breakthroughs have been recently achieved in the tumor diagnosis and therapy field; various new specific antigens have been discovered and the mystery of the diseases genetic basis has been unlocked.. In the next five years, the worlds market for cancer diagnostics is promising to perform as exciting, rapidly evolving and dynamic field. Projected technological breakthroughs are expected to open a wide range of new lucrative opportunities for detecting specific tumors, determining genetic predisposition as well as for monitoring biological response to cancer therapy.. Increasing number of geriatric population worldwide is predicted to give further boost to the demand for malignancy assays and, thus, rapid market expansion at the global level.. Cutting-edge research report 2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales ...
Results from pilot studies indicate that palliative cancer patients report increased well-being and less fatigue after physical activity. This study aimed to explore how palliative cancer patients experienced physical activity. A qualitative design with semi-structured interviews was used. Eleven palliative cancer patients over 18 years old with different diagnoses and Eastern Cooperative Oncology Group Scale performance status levels of between 1 and 3 were interviewed. Four main themes emerged: routines of everyday life, less fatigue, professional guidance, and hope. The first theme comprised two categories: something to do, and being together with others in a similar situation. The theme professional guidance also comprised two categories: the physiotherapist as tutor, and the physiotherapist as motivator. Some cancer patients in palliative care who participated in physical activity experienced less fatigue and enhanced energy. Physical activity helps to bring structure to everyday life and ...
Press Release issued Sep 16, 2013: Reportstack, provider of premium market research reports announces the addition of 2014 Opportunities in the Spanish Cancer Diagnostics Market market report to its offering 2014 Opportunities in the Spanish Cancer Diagnostics Market is a new strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Spanish cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
Whether past history of solid stage I/II inactive cancer has an impact on 28-day mortality of sepsis remains unclear. We aimed to determine the impact of history of stage I or II solid tumor malignancy in complete remission the last 3 years on sepsis outcome. Using the database of the Hellenic Sepsis Study Group from 1553 patients with sepsis admitted in the ICU, 83 patients with sepsis by Sepsis-3 definition with past-history of stage I/II inactive solid malignancy the last 3 years were depicted. A comparator group of 83 patients fully matched for age, severity, type of infection and comorbidities was selected by propensity score matching. Mortality after 28 days was 37.3% in the comparator group and 54.2% in the solid tumor stage I/II group (odds ratio for death 1.98; p: 0.030). Following step-wise forward Cox regression analysis, septic shock (hazard ratio 1.80), acute renal injury (hazard ratio 2.06), history of coronary heart disease (hazard ratio 0.36) and history of stage I/II solid tumor
TY - JOUR. T1 - DNA repair gene variants in relation to overall cancer risk. T2 - A population-based study. AU - Alberg, Anthony J.. AU - Jorgensen, Timothy J.. AU - Ruczinski, Ingo. AU - Wheless, Lee. AU - Shugart, Yin Yao. AU - Berthier-Schaad, Yvette. AU - Kessing, Bailey. AU - Hoffman-Bolton, Judith. AU - Helzlsouer, Kathy J.. AU - Linda Kao, W. H.. AU - Francis, Lesley. AU - Alani, Rhoda M.. AU - Smith, Michael W.. AU - Strickland, Paul Timothy. PY - 2013/1. Y1 - 2013/1. N2 - The hypothesis that germ-line polymorphisms in DNA repair genes influence cancer risk has previously been tested primarily on a cancer site-specific basis. The purpose of this study was to test the hypothesis that DNA repair gene allelic variants contribute to globally elevated cancer risk by measuring associations with risk of all cancers that occurred within a population-based cohort. In the CLUE II cohort study established in 1989 in Washington County, MD, this study was comprised of all 3619 cancer cases ...
TY - JOUR. T1 - Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. AU - Gregorc, Vanesa. AU - De Braud, Filippo G.. AU - De Pas, Tommaso M.. AU - Scalamogna, Roberto. AU - Citterio, Giovanni. AU - Milani, Alessandra. AU - Boselli, Sabrina. AU - Catania, Chiara. AU - Donadoni, Giovanni. AU - Rossoni, Gilda. AU - Ghio, Domenico. AU - Spitaleri, Gianluca. AU - Ammannati, Cristina. AU - Colombi, Scialini. AU - Caligaris-Cappio, Federico. AU - Lambiase, Antonio. AU - Bordignon, Claudio. PY - 2011/4/1. Y1 - 2011/4/1. N2 - Purpose: NGR-hTNF exploits the tumor-homing peptide asparagine-glycine- arginine (NGR) for selectively targeting TNF-α to an aminopeptidase N overexpressed on cancer endothelial cells. Preclinical synergism with cisplatin was displayed even at low doses. This study primarily aimed to explore the safety of low-dose NGR-hTNF combined with cisplatin in resistant/refractory malignancies. Secondary aims included ...
The Annual Report to the Nation on the Status of Cancer finds that from 2001 to 2017, deaths from cancer (all sites combined) continued to decline. The report was released on March 12 and is published in the journal, Cancer.. The annual report, which represents the collaborative efforts of the Centers for Disease Control (CDC), the National Cancer Institute (NCI), the American Cancer Society (ACS), and the North American Association of Central Cancer Registries NAACCR), found decreases in the overall cancer death rates in all major racial and ethnic groups and among men, women, adolescents, young adults, and children. From 2012 to 2016 incidence of new cancers (for all cancers combined) held steady for men and increased slightly for women.. Over a four-year period (2013 to 2017), the report found:. Cancer death rates for men declined in 11 of the 19 most prevalent cancers, remained stable in four cancers (including prostate), and increased in four cancers (oral cavity and pharynx; soft tissue ...
Historically 15- to 39-year-olds have been treated like an overlooked middle child whose parents are too busy lavishing cancer prevention and therapeutic attention on the youngest and oldest, but the Keck School of Medicine of USC is looking to change that dynamic with a first-of-its-kind report card. Published this year, Cancer in Los Angeles County: Trends Among Adolescents and Young Adults 1988-2011 is a large-scale, comprehensive evaluation of the cancer trends of 15- to 39-year- olds, said Dennis Deapen, lead author of the report and director of the Los Angeles Cancer Surveillance Program. There has been tremendous improvement in survival of pediatric cancer patients over the last three decades, Deapen said. Thirty years ago, 80 percent of pediatric cancer patients died of their disease. Now over 80 percent are cured. Yet in what we define as the AYA population, between the ages 15 and 39, there has been no overall improvement in their survival. Cancer is the leading cause of non-accidental
Developing cancer therapies that have minimal side-effects depends upon finding and killing only the cancer cells, leaving the healthy cells alone. To selectively kill cancer cells, a cross-institution team of researchers has developed a technique that targets cancer cells abnormal DNA repair machinery. One member of that team is Alan Tomkinson, PhD, University of New Mexico Professor of Internal Medicine and Associate Director of Basic Research at the UNM Cancer Center. Dr. Tomkinson is an expert in DNA ligases, one of the proteins a cell uses to repair its DNA. He and the team recently published a pair of papers describing their work with chronic myeloid leukemia cells and with breast cancer cells.. In one of the papers, the scientists chose to work with chronic myeloid leukemia cells because, as Dr. Tomkinson explains, Chronic myeloid leukemia is driven by an oncogene called BCR-ABL. We wanted a form of cancer where we knew what the initiating event was. For people with BCR-ABL-driven ...
Head and neck cancer is the sixth most common type of cancer and is on the rise in some demographic groups, including young women without any known risk factors. Now, researchers at Fox Chase Cancer Center report that estrogen may increase the movement of precancerous cells in the mouth and thus promote the spread of the disease within the oral cavity.. The new results, published in the January issue of Cancer Prevention Research, a journal of the American Association for Cancer Research, may lead to novel chemoprevention strategies in the future.. Margie Clapper, Ph.D., co-leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center and Cancer Prevention Research editorial board member, and colleagues had previously reported that estrogen metabolism changes following smoke exposure in the lungs and may contribute to lung cancer. This study on estrogen and lung cancer first appeared in the June 3, 2010, issue of Cancer Prevention Research.. To find out if this female hormone ...
Manoharan, N., Tyagi, B. B., & Raina, V. (2010). Cancer incidences in rural Delhi--2004-05. Asian Pac J Cancer Prev, 11(1), 73-77. Abstract There are no data available on cancer incidence pattern in rural Delhi. This is the first report on cancer incidence among Delhi Rural population during 2004-05 which gives the first hand information on cancer incidence. The data for this report has been collected by Delhi Population based cancer registry. The sources for cancer registration are more than 162 Government Hospitals/centers and 250 private hospitals and nursing homes. A total of 594 cancer cases with 317 males and 277 females were registered during the period 1st January 2004 to 31st December 2005. The age adjusted (world population) incidence rates for all sites were 55.2 per 100,000 for... Show More ...
Nearly, one-fifth of childhood cancer survivors (CCSs) smoke cigars. provision of eight weeks of NRT. The participant initiated treatment enables the participant to contact the QL at their comfort, but contains the same six phone classes and provision of 14 days of NRT. Both groups will receive two follow-up phone calls at 8 weeks and 1 year after enrollment to assess their smoking status. The primary outcome measure is cotinine-validated self-reported smoking abstinence at 1-year follow-up. Results from this study will provide the first evidence about the efficacy of intensive QL cessation intervention in this high risk population. Such evidence can lead as well to the dissemination of this intervention to other medically compromised Crassicauline A IC50 populations. INTRODUCTION There are approximately 270,000 adult survivors of childhood cancer in the US [1]. In 2000, the National Cancer Institute estimated that there were approximately 10 million cancer survivors (adult and child survivors) ...
For example, it turns out that Tide Free & Gentle® isnt so gentle. A report recently released by Womens Voices for Earth, Dirty Secrets: Whats Hiding in Your Cleaning Products? found high levels of the cancer-causing chemical 1,4-dioxane in the detergent. 1,4-dioxane doesnt appear on the product label or on the product website, so consumers have no way of knowing its even there.. This is especially concerning, because Tide Free & Gentle® is marketed to moms as a healthier choice for their childrens laundry. Infants and children are more vulnerable to chemical exposures, because their immune, neurological, and hormone systems are still developing.. 1,4-dioxane is a known cancer-causing chemical, and has been linked in animal studies to increased risk of breast cancer.. Procter & Gamble (makers of Tide®) already have experience stripping 1,4 dioxane out of its products; in 2010, the company reformulated its Herbal Essences® shampoo to eliminate 1,4-dioxane. Unfortunately, Dirty Secrets ...
The number of long-term cancer survivors in the general population of the UK is substantial and increasing rapidly. Many cancer survivors have been treated with radiotherapy but the likely number of radiotherapy-related second cancers has not previously been estimated. We used estimates of the numbers of cancer survivors in the UK at the beginning of 2007, in conjunction with estimates of the relative risk of a second primary cancer associated with previous radiotherapy from the United States Surveillance Epidemiology and End Results (SEER) programme, to estimate the numbers of incident cancers in the UK in 2007 that were associated with radiotherapy for a previous cancer and that may have been caused by it. We estimated that 1,346 cases of cancer, or about 0.45% of the 298,000 new cancers registered in the UK in 2007, were associated with radiotherapy for a previous cancer. The largest numbers of radiotherapy-related second cancers were lung cancer (23.7% of the total), oesophageal cancer (13.3%), and
Advancements such as these have been fuelling growth of the global market for breast cancer diagnostics. Surging cases of breast cancer, coupled with growing older women population are anticipated to create potential growth opportunities for breast cancer diagnostics market across the globe.. The most common type of cancer for women across the globe currently is breast cancer. The number of breast cancer cases is expected to witness a rise, leading towards the requirement for efficient and early breast cancer detection. An established method, mammography, adopted in many countries, has recently been observed to provide inconclusive test results. Personalized and risk-adapted therapy are expected to resolve these difficulties.. You can Get Free Sample Report Here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=55. Estimations for the Global Breast Cancer Diagnostics Market. ...
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion ...
BACKGROUND: Owing to the increasing prevalence of obesity and diabetes in Asia, and the paucity of studies, we examined the influence of raised blood glucose and diabetes on cancer mortality risk. Materials and methods: Thirty-six cohort Asian and Australasian studies provided 367, 361 participants (74% from Asia); 6% had diabetes at baseline. Associations between diabetes and site-specific cancer mortality were estimated using time-dependent Cox models, stratified by study and sex, and adjusted for age. RESULTS: During a median follow-up of 4.0 years, there were 5992 deaths due to cancer (74% Asian; 41% female). Participants with diabetes had 23% greater risk of mortality from all-cause cancer compared with those without: hazard ratio (HR) 1.23 [95% confidence interval (CI) 1.12, 1.35]. Diabetes was associated with mortality due to cancer of the liver (HR 1.51; 95% CI 1.19, 1.91), pancreas (HR 1.78; 95% CI 1.20, 2.65), and, less strongly, colorectum (HR 1.32; 95% CI 0.98, 1.78). There was no evidence
Currently, there are various organizations whose main focus is fighting childhood cancer. Organizations focused on childhood cancer through cancer research and/or support programs include: Childhood Cancer Canada, CLIC Sargent and the Childrens Cancer and Leukaemia Group (in United Kingdom), Child Cancer Foundation (in New Zealand), Childrens Cancer Recovery Foundation (in United States),[32] American Childhood Cancer Organization (in United States),[33] Childhood Cancer Support (Australia) and the Hayim Association (in Israel).[34] Alexs Lemonade Stand Foundation allows people across the US to raise money for pediatric cancer research by organizing lemonade stands.[35] The National Pediatric Cancer Foundation focuses on finding less toxic and more effective treatments for pediatric cancers. This foundation works with 24 different hospitals across the US in search of treatments effective in practice.[36] Childhood Cancer International is the largest global pediatric cancer foundation. It ...
Diagnostic imaging is an essential component of follow-up care for pediatric cancer survivors. However, it carries the risk of causing radiation-induced seco...
Diagnostic imaging is an essential component of follow-up care for pediatric cancer survivors. However, it carries the risk of causing radiation-induced seco...
Neoplasms f. Endocrine, nutritional and metabolic diseases g. Traumatic lesions h. Gingival pigmentation In the second part of ...
... malignant neoplasms intestinal obstruction; decubitus ulcers; dental extraction; sickle cell disease; diabetes mellitus; ...
Neoplasm Metastasis Cancer Brain tumor Tse V (10 November 2009). "Brain Metastasis". Medscape. Retrieved 13 January 2010. " ... Percy AK, Elveback LR, Okazaki H, Kurland LT (January 1972). "Neoplasms of the central nervous system. Epidemiologic ... the national survey of intracranial neoplasms". Neurology. 35 (2): 219-26. doi:10.1212/WNL.35.2.219. PMID 3969210. Tabouret E, ...
Gore RM, Shelhamer RP (October 2007). "Biliary tract neoplasms: diagnosis and staging". Cancer Imaging. 7 Spec No A (Special ...
"DEC1 expression in 1p-aberrant oligodendroglial neoplasms". Histol. Histopathol. 20 (4): 1173-7. PMID 16136500. Yang L, Leung ...
Aug 1993). "Papillary neoplasms (Heffner's tumors) of the endolymphatic sac". Ann. Otol. Rhinol. Laryngol. 102 (8 pt 1): 648-51 ... An endolymphatic sac tumor (ELST) is a very uncommon papillary epithelial neoplasm arising within the endolymphatic sac or ...
EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... para-nasal sinuses and numerous types of benign/malignant neoplasms. The most common sites of EMH associated with neoplastic ...
Berman JJ (November 2004). "Tumor taxonomy for the developmental lineage classification of neoplasms". BMC Cancer. 4 (1): 88. ... system lists a number of morphological subtypes and variants of malignant squamous cell neoplasms, including: Papillary thyroid ...
2003). "Down-regulation of drs mRNA in colorectal neoplasms". Jpn. J. Cancer Res. 93 (8): 888-93. doi:10.1111/j.1349-7006.2002. ...
Coppola, Christopher P.; Merrell, Ronald C. (2001). "Neoplasms of the Adrenal and Endocrine Pancreas in the Elderly". In ...
Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; ...
Sasi, Walid; Sharma, Anup K.; Mokbel, Kefah (2014-03-16). "The Role of Suppressors of Cytokine Signalling in Human Neoplasms". ...
Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ... Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment ... "Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia". JAMA. 297 (11): ...
... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... The Hallmarks of Cancer as evolutionary adaptations in a neoplasm[edit]. In their landmark paper, The Hallmarks of Cancer,[3] ... Cells in neoplasms compete for resources, such as oxygen and glucose, as well as space. Thus, a cell that acquires a mutation ... Genetic heterogeneity in neoplasms[edit]. There are multiple levels of genetic heterogeneity associated with cancer, including ...
Although not a malignant neoplasm like other cancers, MPNs are classified within the hematological neoplasms. There are four ... According to the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 myeloproliferative neoplasms are divided into ... The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405 ...
ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ... Malignant neoplasms[edit]. DNA damage[edit]. The central role of DNA damage and epigenetic defects in DNA repair genes in ...
Neoplasms III D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism ...
Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ...
Neoplasms III D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism ...
Z08) Follow-up examination after treatment for malignant neoplasms. *(Z09) Follow-up examination after treatment for conditions ...
Most hepatectomies are performed for the treatment of hepatic neoplasms, both benign or malignant. Benign neoplasms include ... The most common malignant neoplasms (cancers) of the liver are metastases; those arising from colorectal cancer are among the ...
Malignant neoplasm of liver and intrahepatic bile ducts. The most frequent forms are metastatic malignant neoplasm of liver) ... by Echinococcus Polycystic liver disease Amyloid degeneration of liver malignant neoplasm of the gallbladder malignant neoplasm ... hepatoma cholangiocarcinoma hepatoblastoma angiosarcoma of liver Kupffer cell sarcoma other sarcomas of liver Benign neoplasm ...
Neoplasms include: *Pheochromocytoma (most common), a catecholamine-secreting tumor of the adrenal medulla[1][5] ...
The small intestine is found in all tetrapods and also in teleosts, although its form and length vary enormously between species. In teleosts, it is relatively short, typically around one and a half times the length of the fish's body. It commonly has a number of pyloric caeca, small pouch-like structures along its length that help to increase the overall surface area of the organ for digesting food. There is no ileocaecal valve in teleosts, with the boundary between the small intestine and the rectum being marked only by the end of the digestive epitheliu.[22] In tetrapods, the ileocaecal valve is always present, opening into the colon. The length of the small intestine is typically longer in tetrapods than in teleosts, but is especially so in herbivores, as well as in mammals and birds, which have a higher metabolic rate than amphibians or reptiles. The lining of the small intestine includes microscopic folds to increase its surface area in all vertebrates, but only in mammals do these develop ...
Neoplasm. {{Epithelial neoplasms}}. Medicine. Glandular and epithelial neoplasms (ICD-O 8010-8589). Oncology templates. See ... Neoplasm. {{Tumors}}. Medicine. Pathology: Tumor, Neoplasm, Cancer, and Oncology (C00-D48, 140-239). Oncology templates. Footer ... Eye neoplasm (C69/D31, 190/224). Oncology templates. Footer. Pathology. Sense Organs. {{Eponymous medical signs for eyes and ... Neoplasm. {{Paraneoplastic syndromes}}. Medicine. Paraneoplastic syndromes. Oncology templates. Footer. Composite format.. ...
Ovarian neoplasms Germ cell tumor Seen most often in young women or adolescent girls. Other germ cell tumors are: Endodermal ...
These enhance angiogenesis and aid in the growth of UV-induced neoplasms. It has been reported that UV radiation leads to local ...
In obstetrics and gynecology contexts, it is a form of adenomyosis that forms a mass or growth around the tissue of the inner uterus. Most cases of adenomyosis are non-symptomatic. However, it may present with dysmenorrhea and pelvic pain. In the case of juvenile cystic adenomyoma, laparoscopic enucleation results in a statistically and clinically significant reduction in dysmenorrhea, ease in any chronic pelvic pain, and low risk of recurrence.[2] ...
Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ...
Salivary gland neoplasms *Benign: Basal cell adenoma. *Canalicular adenoma. *Ductal papilloma. *Monomorphic adenoma ...
Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are ... The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and ... Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are ... Critical Issues About the Diagnosis of Myeloproliferative Neoplasms: World Health Organization Classification ...
Neoplasms. Br Med J 1951; 2 doi: https://doi.org/10.1136/bmj.2.4745.1446-a (Published 15 December 1951) Cite this as: Br Med J ...
Endocrine neoplasms; Islet cell tumors (pancreatic NET); Small cell and large cell... ... Schmitt-Graeff A. (2015) Neuroendocrine Neoplasms. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. * ... Carcinoid (well differentiated neuroendocrine tumor (NET) of the respiratory and gastrointestinal tract); Endocrine neoplasms; ... Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18:S1-S16 ...
ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term neoplasm is a synonym of "tumor". Neoplasia denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ... Malignant neoplasms[edit]. DNA damage[edit]. The central role of DNA damage and epigenetic defects in DNA repair genes in ...
This presentation is prepared for undergraduate students about the various myeloproliferative neoplasms with updated ... Myeloproliferative neoplasms for students * 1. By Dr MONKEZ MYOUSIF Professor of Internal Medicine Zagazig university 2016 ... A. Other myeloproliferative neoplasms (CML, CIMF, PV) B. Myelodysplastic syndromes (MDS) C. Secondary thrombocytosis − ... This presentation is prepared for undergraduate students about the various myeloproliferative neoplasms with updated ...
All MeSH CategoriesDiseases CategoryNeoplasmsNeoplasms by SiteUrogenital NeoplasmsUrologic NeoplasmsKidney NeoplasmsCarcinoma, ... All MeSH CategoriesDiseases CategoryMale Urogenital DiseasesUrogenital NeoplasmsUrologic NeoplasmsKidney NeoplasmsCarcinoma, ... Urogenital Diseases and Pregnancy ComplicationsFemale Urogenital DiseasesUrogenital NeoplasmsUrologic NeoplasmsKidney Neoplasms ... All MeSH CategoriesDiseases CategoryMale Urogenital DiseasesUrologic DiseasesKidney DiseasesKidney NeoplasmsCarcinoma, Renal ...
Bladder Neoplasms. Br Med J 1970; 2 doi: https://doi.org/10.1136/bmj.2.5705.351-b (Published 09 May 1970) Cite this as: Br Med ...
NeoplasmsNeoplasms by SiteNervous System NeoplasmsCentral Nervous System NeoplasmsBrain NeoplasmsCerebral Ventricle Neoplasms ... NeoplasmsBrain Stem NeoplasmsCerebellar NeoplasmsNeurocytomaPinealomaSupratentorial NeoplasmsHypothalamic Neoplasms + ... NeoplasmsBrain Stem NeoplasmsCerebellar NeoplasmsNeurocytomaPinealomaSupratentorial NeoplasmsHypothalamic Neoplasms + ... Nervous System NeoplasmsCentral Nervous System NeoplasmsBrain NeoplasmsCerebral Ventricle NeoplasmsChoroid Plexus Neoplasms + ...
Although not a malignant neoplasm like other cancers, MPNs are classified within the hematological neoplasms. There are four ... According to the WHO Classification of Hematopoietic and Lymphoid Neoplasms 2008 myeloproliferative neoplasms are divided into ... The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405 ...
This is a chart to show the publishing history of editions of works about this subject. Along the X axis is time, and on the y axis is the count of editions published. Click here to skip the chart. Reset chart or continue zooming in. This graph charts editions published on this subject. ...
Pancreatic neuroendocrine neoplasms (P-NENs) are a group of pathologically and clinically heterogeneous tumors. In the past ... Neuroendocrine neoplasms (NENs) once called carcinoid tumors, endocrine tumors or neuroendocrine tumors (NETs) are a group of ... Pancreatic neuroendocrine neoplasms (P-NENs), commonly be called pancreatic endocrine tumors, insulinoma, gastrinoma or ...
Sinus Center provides state-of-the-art care to patients with sinus and allergy disorders including treatment of neoplasms. ... Conditions We Treat: Neoplasms. A neoplasm, typically a benign tumor, can behave more aggressively if not fully treated, rarely ... Neoplasms: What You Need to Know. *Some malignant tumors that occur in the nose include esthesioneuroblastoma (olfactory ... in the Head and Neck Cancer Surgery Center and the Department of Neurology and Neurosurgery to treat patients with neoplasms. ...
Myeloproliferative neoplasms are a type of blood cancer that includes myelofibrosis, polycythemia vera and essential ... Myeloproliferative Neoplasms. Myeloproliferative neoplasms are a type of blood cancer that includes myelofibrosis, polycythemia ... Myeloproliferative neoplasms (MPNs) are types of blood cancer that begin with an abnormal mutation (change) in a stem cell in ... Is one of a related group of blood cancers known as "myeloproliferative neoplasms (MPNs)" in which bone marrow cells that ...
A number of studies have examined the most common chronic condition clusters in men and women (Ashman et al. 2013, Lochner et al. 2013, Steiner et al. 2013, Steinman et al. 2012, Ward et al. 2013). Exhibit 6 contains chronic condition dyads (2) and triads (3) that were examined in the studies. Although many chronic condition clusters, such as hype ...
... sessions on myeloproliferative neoplasms (MPNs) will take place at the ASH Meeting on Hematologic Malignancies. ... How I Treat Myeloproliferative Neoplasms. The following "How I Treat" sessions on myeloproliferative neoplasms (MPNs) took ... He is a physician investigator with a career focus on developing new therapies for patients with myeloproliferative neoplasms ... Ruben Mesa will discuss how he treats problematic cases of patients with the myeloproliferative neoplasms of essential ...
I was wondering if anyone has experience using the Morphology of Neoplasm codes for billing purposes. Can they/should they be ... I was wondering if anyone has experience using the Morphology of Neoplasm codes for billing purposes. Can they/should they be ...
This workshop summary highlights the role of molecular genetic testing in the diagnosis of lymphoid neoplasms, as well as its ... Table 6. Histiocytic Neoplasms Case No.. Panel Diagnosis. Genetic Findings. 135. Orbital mass: Langerhans cell histiocytosis ( ... Low-grade lymphoid neoplasms with genetic events associated with aggressive biology. 36. Chronic lymphocytic leukemia. t(8;14 ... T-cell neoplasms. FISH for inv(14), iso(7q), ALK, DUSP22, TP63 rearrangement. ...
Plasma cell neoplasms are a group of diseases - some cancerous - where certain blood cells dont work like they should. Learn ... Plasma cell neoplasms can lead to amyloidosis. This is a condition where proteins build up in your organs, like the kidneys and ... In some plasma cell neoplasms, the cells are cancer and form tumors, usually in your bones. The symptoms you get and the ... But with the group of diseases known as plasma cell neoplasms, your body makes too many plasma cells. They make an antibody ...
NCCN Guidelines for Patients® , Myeloproliferative Neoplasms. 47 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms ...
CancerCares Co-Payment Assistance Fund helps people with myeloproliferative neoplasms access the prescribed treatments they ... CancerCare offers support services for people with myeloproliferative neoplasms including counseling, support groups, financial ... Myeloproliferative Neoplasms. Helping people with cancer access the prescribed treatments they need. This includes Essential ...
NCCN Guidelines for Patients® , Myeloproliferative Neoplasms. 71 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms ...
Population served: People diagnosed with a myeloproliferative neoplasm (MPN) worldwide. Other language(s): Spanish. Mission: To ... To provide a comprehensive, easy to navigate resource hub for the study of Myeloproliferative Neoplasms (MPNs) such as ... Patients Support Resources Other Helpful Organizations Blood Cancer - General Information Myeloproliferative Neoplasms ... Population served: Patients diagnosed with Myeloproliferative Neoplasms (MPNs), caregivers, professionals. Mission: To empower ...
Primary brain tumors arise from CNS tissue and account for roughly half of all cases of intracranial neoplasms. ... encoded search term (Brain Neoplasms) and Brain Neoplasms What to Read Next on Medscape ... Brain Neoplasms. Updated: Jan 02, 2019 * Author: Bruce M Lo, MD, MBA, CPE, RDMS, FACEP, FAAEM, FACHE; Chief Editor: Barry E ... Neoplasms, brain. CT images of several tumor types. Slide courtesy of UMASS Continuing Education Office. View Media Gallery ...
Neo*plasm (?), n. [See Neoplasia.] Physiology|Physiol. & Medicine|Med. A new formation or tissue, the product of morbid action...
Neoplasm News and Research. RSS Neoplasm is an abnormal mass of tissue as a result of neoplasia. Further Reading. *Neoplasm - ... Common drug for autoimmune disease may increase risk of myeloid neoplasms Mayo Clinic researchers have found that azathioprine ... infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients, two years of ... a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. ...
... are a group of clonal myeloid cell-derived disorders characterized by myeloproliferation without ... Jones AV, Chase A, Silver RT, et al: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms ... Mehta J, Wang H, Iqbal SU, et al: Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2013:1-6, ... Myeloproliferative neoplasms are a group of clonal myeloid cell-derived disorders characterized by myeloproliferation without ...
The Myeloproliferative Neoplasms Online Medical Reference - definition, incidence, pathophysiology and natural history, signs ... Mutations of JAK2, MPL, or CALR occur in most myeloproliferative neoplasms and serves as a pivotal diagnostic criterion. ... The myeloproliferative neoplasms (MPNs), previously termed the myeloproliferative disorders, are characterized by the clonal ... The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2014; 2014:287-296. ...
Digestive System Neoplasms Clinical Research Trial Listings in Gastroenterology Oncology Hepatology (Liver, Pancreatic, Gall ... Digestive System Neoplasms Clinical Trials. A listing of Digestive System Neoplasms medical research trials actively recruiting ...
... the diagnosis and treatment of salivary gland neoplasms remain com... ... Neoplasms that arise in the salivary glands are relatively rare, yet they represent a wide variety of both benign and malignant ... Salivary gland neoplasms make up 6% of all head and neck tumors. [1] The incidence of salivary gland neoplasms as a whole is ... Parotid neoplasms most commonly occur in the tail of the gland. Submandibular neoplasms often appear with diffuse enlargement ...
STEWART, A., KNEALE, G. Role of Local Infections in the Recognition of Haemopoietic Neoplasms. Nature 223, 741-742 (1969). ... Role of Local Infections in the Recognition of Haemopoietic Neoplasms. *ALICE STEWART1. & ...